Clostridium difficile: nowości diagnostyczne i terapeutyczne

Clostridium difficile: diagnostic and therapeutic news

Gajane Martirosian, Monika Kabała

Katedra i Zakład Mikrobiologii Lekarskiej Wydziału Śląskiego Uniwersytetu Medycznego w Katowicach

Gajane Martirosian
Katedra i Zakład Mikrobiologii Lekarskiej Wydziału Lekarskiego w Katowicach
Śląskiego Uniwersytetu Medycznego,
ul Medyków 18, 40-752 Katowice
Tel./Fax: 32 208 85 50 / 32 252 60 75

Wpłynęło: 16.11.2018
Zaakceptowano: 17.12.2018
Opublikowano on-line: 28.12.2018

Cytowanie

Martirosian G, Kabała M. Clostridium difficile: nowości diagnostyczne i terapeutyczne.
Zakażenia XXI wieku 2018;1(6):295–302.
doi: 10.31350/zakazenia/2018/6/Z2018053

WERSJA ELEKTRONICZNA

Streszczenie:
Zakażenia Clostridioides (Clostridium) difficile (CDI) są trudnym problemem medycznym, terapeutycznym i ekonomicznym na całym świecie. Od początku XXI wieku zakażenia są cięższe, nawet powodują zgon pacjenta. W związku z powyższym podjęto działania mające na celu ujednolicenie diagnostyki tych zakażeń, a także ich leczenia i postępowania epidemiologicznego. Nowe rekomendacje dotyczące diagnostyki i leczenia CDI powstały w USA, Europie, również w Polsce. W tym artykule przedstawimy problemy diagnostyki i leczenia CDI w świetle ostatnich rekomendacji, akcentując zmiany dotyczące zarówno diagnostyki, jak i leczenia CDI.

Słowa kluczowe: zakażenia Clostridium difficile, diagnostyka, leczenie

Abstract:
Clostridioides (Clostridium) difficile infections (CDI) pose a serious medical, therapeutic and economic problem throughout the world. Since the beginning of the 21st century, we have been observing a new quality – infections are more severe and even fatal. Therefore, a decision was taken to standardize the diagnostics of these infections, as well as their treatment and epidemiological procedures. New recommendations regarding the diagnostics and treatment of CDI have been published in the USA, Europe, as well as in Poland. In this article, we will present the problems of diagnostics and treatment of CDI in the light of the recent recommendations.

Key words: Clostridium difficile infection, diagnostics, treatment

  1. Bartlett JG, Onderdonk AB, Cisneros RL i wsp. Clindamycin-associated colitis due to a toxin-producing species of C. difficile. J Infect Dis 1977;136:701–705.
  2. Martirosian G. Zmiany w epidemiologii, klinice, diagnostyce i leczeniu zakażeń Clostridium difficile. Zakażenia 2013;2:53–58.
  3. Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prévot 1938. Anaerobe 2016;40:95–99 [doi: 10.1016/j.anaerobe.2016.06.008].
  4. Pepin J, Alary ME, Valiquette L i wsp. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40(11):1591–1597 [doi: 10.1086/430315].
  5. McDonald LC, Killgore GE, Thompson A i wsp. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353(23):2433–2441 [doi: 10.1056/NEJMoa051590].
  6. Kelly CP, La Mont JT. Clostridium difficile – more difficult than ever. N Engl J Med 2008;359(18):1932–1940 [doi: 10.1056/NEJMra0707500.]
  7. Davies KA, Longshow CM, Davis GL i wsp. Under diagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalized patients with diarrhoea (EUCLID). Lancet Infect Dis 2014;14(12):1208–1219 [doi: 10.1016/S1473-3099(14)70991-0].
  8. Pituch H, Obuch-Woszczatyński P, Lachowicz D i wsp. Hospital-based Clostridium difficile infection surveillance reveals high proportions of PCR ribotypes 027 and 176 in different areas of Poland 2011–2013. Euro Surveil 2015;20(38):30025 [doi: .2807/1560-7917.ES.2015.20.38.30025].
  9. Aptekorz M, Szczegielniak A, Wiechuła B i wsp. Occurrence of Clostridium difficile ribotype 027 in hospitals of Silesia, Poland. Anaerobe 2017;45:106–113 [doi: 10.1016/j.anaerobe.2017.02.002].
  10. Tschudin-Sutter S, Kuijper EJ, Durovic A i wsp. Guidance document for prevention of Clostridium difficile infection in acute healthcare setting. Clin Microbiol Infect 2018;24(10):1051–1054 [doi: 10.1016/j.cmi.2018.02.020].
  11. ECDC: European surveillance of Clostridium difficile infections. Surveillance protocol version 2.3. Stockholm; ECDC 2017.
  12. Crobach MJT, Planche T, Eckert C i wsp. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 2016;22(Suppl. 4):S63–S81 [doi: 10.1016/j.cmi.2016.03.010].
  13. McDonald LC, Gerding DN, Johnson S i wsp. Clinical practice guidelines for Clostridium difficile infection in adult and children: 2017 update by the IDSA and SHEA. Clin Infect Dis 2018;XX(00):1–49.
  14. Martirosian G, Hryniewicz W, Ozorowski T i wsp. Zakażenia Clostridioides (Clostridium) difficile: epidemiologia, diagnostyka, terapia i profilaktyka. Ministerstwo Zdrowia, NPOA, Warszawa 2018. www.antybiotyki.edu.pl
  15. Péchiné S, Collignon A. Immune responses induced by Clostridium difficile. Anaerobe 2016;41:68–78 [doi: 10.1016/j.anaerobe.2016.04.014].
  16. Eyre DW, Davies KA, Davis G i wsp. Two distinct patterns of Clostridium difficile diversity across Europe indicating contrasting routes of spread. Clin Infect Dis 2018;67(7):1035–1044 [doi: 10.1093/cid/ciy252].
  17. Ticehurst J, Aird D, Dam L i wsp. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006;44(3):114–119 [doi: 10.1128/JCM.44.3.1145-1149.2006].
  18. Berry CE, Davies KA, Owens DW i wsp. Is there a relationship between the presence of the binary toxin genes in C. difficile strains and the severity of Clostridium difficile infection (CDI)? Eur J Clin Microbiol Infect Dis 2017;6(12):2405–2415 [doi: 10.1007/s10096-017-3075-3078[.
  19. Planche T, Wilcox M. Diagnostic pitfalls in Clostridium difficile infection. Infect Dis Clin North Am 2015;29(1):63–82 [doi: 10.1016/j.idc.2014.11.008].
  20. Debast S, Bauer M, Kuijper E, on behalf of the Committee. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20(Suppl. 2):1–26 [doi: 10.1111/1469-0691.12418].
  21. Cammarota G, Masucci I, Ianiro G i wsp. Randomized clinical trial fecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent C. difficile infection. Aliment Pharmacol Ther 2015;41(9):835–843 [doi: 10.1111/apt.13144].
  22. Youngster I, Sauk J, Pindat C, i wsp. Fecal microbiota transplant for relapsing C. difficile infection using a frozen inoculum from unrelated donor: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014;58(1):1515–1522 [doi: 10.1093/cid/ciu135].
  23. Enoch DA, Butler MJ, Pai S, Karas JA. Clostridium difficile in children: colonisation and disease. J Infect 2011;63(2):105–113 [doi: 10.1016/j.jinf.2011.05.016].
  24. Toltzis P, Kim J, Dul M i wsp. Presence of epidemic North American Pulsed Field type 1 C. difficile strain in hospitalized children. J Pediatr 2009;28(9):847–848.
  25. Stoesser N, Eyre DW, Quan TP i wsp. Epidemiology of Clostridium difficile in infants in Oxfordshire, UK: Risk factors for colonization and carriage, and genetic overlap with regional C. difficile infection strains. PloS One 2017;16:12(8):e0182307 [doi: 10.1371/journal.pone.0182307].
  26. Parsons S, Fenton E, Dargaville P. C. difficile-associated severe enterocolitis a future of Hirschsprung’s disease in a neonate presenting late. J Paediatr Child Health 2005;41:689–690.
  27. Gonzalez-Del Vecchio M, Alvarez-Uria A, Marin M i wsp. Clinical significance of C. difficile in children less than 2 years old: a case-control study. Pediatr Infect Dis J 2016;53:281–285.

Konflikt interesów: nie zgłoszono.
Praca została wykonana w ramach pracy statutowej WLK SUM: KNW-1-061/K/8/0

MAVIPURO POLSKA Sp. z o.o.
ul. Wyspowa 2/13
03-687 Warszawa
Tel.: +48 22 110 03 81
Fax:   +48 22 378 28 51
e-mail: kontakt@mavipuro.pl

 

POLITYKA PRYWATNOŚCI